Loading...
XKRX
950130
Market cap207mUSD
Aug 14, Last price  
9,060.00KRW
Name

Access Bio Inc

Chart & Performance

D1W1MN
XKRX:950130 chart
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.30%
Rev. gr., 5y
21.17%
Revenues
112.46b
-67.74%
36,997,543,00045,840,015,00032,305,084,00035,582,621,00032,485,928,00029,464,754,00040,239,207,00043,058,688,000121,797,380,000505,111,695,0001,033,863,094,000348,643,147,000112,462,797,000
Net income
-348m
L-89.05%
7,451,130,0007,838,027,0002,432,290,0001,265,161,000304,159,000-6,485,782,000-4,240,612,000-20,656,016,00048,272,499,000189,689,851,000346,670,216,000-3,172,838,000-347,576,000
CFO
19.90b
P
1,845,660,0001,587,126,000-2,748,909,0002,865,213,0002,553,507,000-5,445,311,000-5,730,652,000-422,239,00036,722,089,000163,476,864,000369,197,603,000-103,882,450,00019,904,217,000
Dividend
Dec 28, 2022871 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.
URL
https://accessbio.net/
IPO date
May 30, 2013
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT